arrow
A

Anna Kron

University of Cologne
H指数:18
被引数:1,678

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Implementation of patient-reported outcomes in personalized lung cancer care: a qualitative study from the perspective of patients and health care providers

从患者和医疗保健提供者角度实施患者报告结局在个性化肺癌护理中的应用:一项定性研究

2026-05-010
PRE
Concept and feasibility of privacy-preserving record linkage of cancer registry data and claims data in Germany: results from the DigiNet study on stage IV non-small cell lung cancer

隐私保护记录链接的概念与可行性:德国癌症登记数据与理赔数据在IV期非小细胞肺癌方面的研究——DigiNet研究的结果

2025-12-040
OAAI
Germany’s national genomDE strategy

德国国家基因组策略

2025-10-150
PRE
DigiNet: Optimizing personalized care for patients with stage IV non-small cell lung cancer (NSCLC) through a digitally connected provider network–analysis plan of a prospective multicenter cohort trial

DigiNet:通过数字连接的医疗服务提供者网络优化IV期非小细胞肺癌(NSCLC)患者的个性化护理——前瞻性多中心队列试验的分析计划

2025-09-090
OAAI
Treatment Sequences in BRAF-V600–Mutated NSCLC: First-Line Targeted Therapy Versus First-Line (Chemo-) Immunotherapy

BRAF-V600-Mutated NSCLC的治疗顺序: 一线靶向治疗与一线 (化疗) 免疫治疗

2025-05-080
OAAI
Response to letter entitled: Re: Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations

回复标题为:关于从GEOMETRY mono-1试验中获取的卡马替尼治疗与德国局部晚期或转移性NSCLC患者中METex14跳跃突变患者的标准治疗(SOC)的间接比较的来信

2024-12-010
PRE
Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations [Eur J Cancer 207 (2024) 114158]
2024-12-010
OAAI
Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS Q61 mutations

携带KRAS Q61突变非小细胞肺癌(NSCLC)患者的分子和临床特征

2024-09-010
PRE
Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations
2024-08-012
OAAI
An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Amivantamab与欧洲和美国实际临床实践对表皮生长因子受体外显子20插入突变激活的晚期非小细胞肺癌患者的调整治疗比较

2023-01-189
OAAI
Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
2018-11-07111
OAAI
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer
2018-10-01130
OAAI